Fresh Tracks Therapeutics Fresh Tracks Therapeutics Home
  • Company
    • Vision
    • Values
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partner With Us
    • Join Us
  • Scientific Innovations
  • Pipeline
    • Overview
    • FRTX-02
    • FRTX-10
    • Next-Generation Kinase Inhibitors
    • FRTX-03
  • Investor Relations
Main Menu
Contact Us
Investor Relations

News

Investors

Investors

  • Overview
  • News
  • Events
  • Presentations
  • Governance
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
Jul 01, 2022 2:02pm EDT

Brickell Biotech Announces 1-For-45 Reverse Stock Split

May 19, 2022 8:00am EDT

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

May 12, 2022 4:01pm EDT

Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 05, 2022 4:01pm EDT

Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022

May 03, 2022 4:02pm EDT

Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders

May 03, 2022 4:01pm EDT

Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals

Mar 15, 2022 7:30am EDT

Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 10, 2022 8:00am EST

Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Study Results for Sofpironium Bromide Gel, 15% at the 2022 AAD Annual Meeting

Mar 08, 2022 4:05pm EST

Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 15, 2022

Feb 02, 2022 7:30am EST

Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Next Pagearrow_forward
  • Email Alerts
  • RSS News Feed

Company

  • Vision
  • Values
  • Leadership
  • Partner With Us
  • Join Us

Discover

  • Scientific Innovations
  • Pipeline
  • Investor Relations
  • News
  • Contact Us

Follow Us

  • LinkedIn
  • Twitter
  • Instagram
  • Facebook
  • Compliance
  • Terms of Use
  • Privacy Policy
  • Accessibility
©2023 Fresh Tracks Therapeutics, Inc.

We use first- and third-party cookies to obtain statistical information to personalize our website and provide you with a better experience. If you continue without changing your settings, this demonstrates your consent to receive all cookies or other tracking technologies on the FRTX website for the purposes described in our Privacy Policy. Please know that you can change your cookie settings at any time in your browser settings.

Close